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Abstract
Background: A totally implantable venous access device (TIVAD) provides reliable, long-term vascular access and
improves patients’ quality of life. The wide use of TIVADs is associated with important complications. A meta-analysis
was undertaken to compare the internal jugular vein (IJV) with the subclavian vein (SCV) as the percutaneous access
site for TIVAD to determine whether IJV has any advantages.
Methods: All randomized controlled trials (RCTs) and cohort studies assessing the two access sites, IJV and SCV, were
retrieved from PubMed, Web of Science, Embase, and OVID EMB Reviews from their inception to December 2015.
Random-effects models were used in all analyses. The endpoints evaluated included TIVAD-related infections, catheter-
related thrombotic complications, and major mechanical complications.
Results: Twelve studies including 3905 patients published between 2008 and 2015, were included. Our meta-
analysis showed that incidences of TIVAD-related infections (odds ratio [OR] 0.71, 95 % confidence interval [CI]
0.48–1.04, P = 0.081) and catheter-related thrombotic complications (OR 0.76, 95 % CI 0.38–1.51, P = 0.433) were
not significantly different between the two groups. However, compared with SCV, IJV was associated with reduced risks
of total major mechanical complications (OR 0.38, 95 % CI 0.24–0.61, P < 0.001). More specifically, catheter dislocation (OR
0.43, 95 % CI 0.22–0.84, P = 0.013) and malfunction (OR 0.42, 95 % CI 0.28–0.62, P < 0.001) were more prevalent in the SCV
than in the IJV group; however, the risk of catheter fracture (OR 0.47, 95 % CI 0.21–1.05, P = 0.065) were not significantly
different between the two groups. Sensitivity analyses using fixed-effects models showed a decreased risk of catheter
fracture in the IJV group.
Conclusion: The IJV seems to be a safer alternative to the SCV with lower risks of total major mechanical complications,
catheter dislocation, and malfunction. However, a large-scale and well-designed RCT comparing the complications of
each access site is warranted before the IJV site can be unequivocally recommended as a first choice for percutaneous
implantation of a TIVAD.
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Background
Since Niederhuber et al. first introduced the totally im-
plantable venous access device (TIVAD) at the MD
Anderson Cancer Center in 1982 [1], TIVAD systems
have gained worldwide popularity in oncology patients
[2]. The number of implanted TIVADs is increasing,
with more than 400,000 sold each year in the USA [3].
The use of a TIVAD allows for the long-term adminis-
tration of venotoxic compounds, reduces the risk of in-
fection, markedly alleviates the burden of intravenous
therapy and thereby improves these patients’ quality of
life, as this device does not require any external dressing.
[3–5] Nevertheless, approximately 15 % of patients ex-
perience catheter-related complications [6]. The im-
plantation of a TIVAD can be performed by different
methods, such as percutaneous insertion and surgical
venous cut-down [5, 7]. Even through, percutaneous
TIVAD insertion has become the preferred method of
implantation worldwide [5].
Several meta-analyses [8, 9] and the latest review [10]
have recommended the routine utilization of ultrasound
guidance in practice. With the help of ultrasound guid-
ance, the percutaneous approach has the lowest rate of
early complications [11]. Oncologists are most con-
cerned with long-term complications occurring during
the use of TIVADs [12]. Because the internal jugular
vein (IJV) and subclavian vein (SCV) are the most com-
mon access sites to implant catheters in the superior
vena cava (SVC) for long-term use [13, 14], it would be
helpful to know which site is associated with fewer com-
plications in the long-term follow-up.
Although several studies comparing the IJV and the
SCV have been reported, most are small series of pa-
tients with conflicting results [15–18]. To date, neither
valid recommendations nor guidelines concerning the
choice of access site and long-term complications of
TIVADs have been elaborated. In this meta-analysis, we
sought to assemble the most robust dataset currently
available to address a single focused clinical question:
which access site, the IJV or the SCV, has fewer late




We performed the meta-analysis in accordance with the
Meta-analysis Of Observational Studies in Epidemiology
(MOOSE) guidelines and the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement [19, 20]. Eligible studies were searched in online
databases including PubMed, Embase, Web of Science,
and OVID EMB Reviews, from inception to December
2015. A variety of synonyms for “totally implantable ven-
ous device”, “internal jugular vein”, and “subclavian vein”
were combined. The complete search process is presented
in Table 1. A manual search of the citations and references
in the articles retrieved for full review was conducted to
Table 1 Search process
Database Search filter Results
PubMed ("Catheterization, Central Venous/adverse effects"[Mesh] OR "Catheterization,
Central Venous/methods"[Mesh] OR "Catheters, Indwelling/adverse effects"
[Mesh]) AND ((totally implantable*[tiab]) OR (TIV*[tiab]) OR (port[tiab]) OR
(ports[tiab])) AND ((jugular*[tiab]) OR (subclavian*[tiab]))
236 articles
Web of Sciencea #1 TOPIC: (totally implantable venous port*) Timespan = All years Search
language = Auto
#2 TOPIC: (totally implantable venous device*) Timespan = All years Search
language = Auto
#3 TITLE: (port-a-cath* OR TIVA* OR port OR ports) Timespan = All years
Search language = Auto
#4 TOPIC: (jugul* OR subclavian*) Timespan = All years Search language = Auto
#5 (#3 OR #2 OR #1)
#6 (#5 AND #4)
865 articles
Embase #1 implant* NEAR/5 (port OR ports OR device OR devices OR system OR systems)
#2 TIVAP:ab OR TIVP:ab OR TIVAD:ab OR port:ab OR CVAP:ab
#3 jugul*:ab OR subclavian*:ab
#4 #1 OR #2
#5 #3 AND #4 AND ([article]/lim OR [article in press]/lim OR [conference
abstract]/lim OR [conference paper]/lim OR [review]/lim) AND [humans]/lim
944 articles
All OVID Evidence-Based Medicine Reviewsb #1 (implant* and (port or device or system)).mp. [mp = ti, ot, ab, tx, kw, ct, sh, hw]
#2 (TIVAP or TIVAD or TIVP or TICVP).mp. [mp = ti, ot, ab, tx, kw, ct, sh, hw]
#3 (jugul* or subclavian*).mp. [mp = ti, ot, ab, tx, kw, ct, sh, hw]
#4 #1 or #2
#5 #3 AND #4
61 articles
aIncluding Web of ScienceTM Core Collection, BIOSIS preview®, Chinese Science Citation DatabaseSM, Derwent Innovations IndexSM, Inspect®, KCI-Korean Journal
Database, MEDLINE®, SciELO Citation Index
bIncluding Cochrane DSR, ACP Journal Club, DARE, CCTR, CMR, HTA, and NHSEED
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identify the potentially eligible studies. No limitations
were placed on the time period of the trial or the reporting
language. Authors were contacted for additional informa-
tion if necessary.
Inclusion and exclusion criteria
All available randomized controlled trials (RCTs),
non-randomized cohort studies that compared the IJV
with the SCV as the puncture site for a TIVAD in all
age groups, were included. Letters, editorials, case re-
ports, review articles, and animal experimental studies
were excluded. In order to make the clinical hetero-
geneity between studies smaller, the studies with
follow-up less than 180 days were excluded. If a study
investigated multiple access sites (IJV, SCV, and ceph-
alic vein) [16, 18, 21], only the data from the IJV and
the SCV were included.
Data collection
Data extraction was performed by two independent
authors (SYW and JXH). Agreement between the two
reviewers was measured using the k statistic. Any
discrepancies were resolved by discussion with the
remaining authors. Demographics, clinical characteristics
(age, brand of TIVAD used) and technique used (IJV
percutaneous insertion, SCV percutaneous insertion,
with or without ultrasound guidance or fluoroscopy)
were collected. The complications of TIVAD were cate-
gorized into infectious complications, thrombotic com-
plications, and mechanical complications [22, 23].
The primary outcomes were the incidence of TIVAD-
related infections and thrombotic complications from
the time of TIVAD insertion to TIVAD removal or the
end of study; TIVAD-related infections were defined ac-
cording to updated guidelines by the Infectious Diseases
Society of America [24] and included pocket infection,
local infection, and catheter-related bloodstream infec-
tion [25]. Catheter-related thrombotic complications
were defined as a mural thrombus extending from the
catheter into the lumen of a vessel and leading to partial
or total catheter occlusion, with or without clinical
symptoms (including fibrin sheath, deep vein throm-
bosis, major and complete thrombosis), [26, 27] which
would be diagnosed using Doppler ultrasound, [15]
follow-up chest radiography or chest computed tomog-
raphy [17]. The secondary outcome was the rate of
major mechanical complications after insertion of the
TIVAD and follow-up. Major mechanical complications
were defined in accordance with the Clavien-Dindo clas-
sification of surgical complications (grade III /IV/V)
[28], including catheter malfunction (including infusion
malfunction, aspiration malfunction, a combination of
both, namely catheter occlusion [29]), catheter disloca-
tion (also called malposition/migration; namely, the tip
of catheter lying in a different vein from the intended
superior vena cava [30]), catheter fracture (breakage or
fracture of the catheter, including the breakage or dis-
connection of junction between the catheter and the res-
ervoir, with or without embolism by catheter fragments),
pinch-off syndrome, port rotation, port extrusion,
hemorrhage, and extravasation. In addition, if there were
more than three included studies and the complication
was common, the data for a single major mechanical
complication was pooled for meta-analysis. Late compli-
cations were unlikely to be due to the port implantation
procedure itself [4], so immediate mechanical complica-
tions, such as pneumothorax, arterial puncture, and
hematoma, which were procedure-related, were ex-
cluded in this meta-analysis. Other immediate mechan-
ical complications such as primary malposition, which
could be solved immediately with or without fluoro-
scopic control [15], were not included in this study.
Above all, immediate mechanical complications were
not included in this study. In addition, minor mechan-
ical complications (Clavien-Dindo grade I/II), such as
catheter looping, [31] were also excluded.
Quality assessment
The quality of RCTs was assessed using the Cochrane Col-
laboration’s tool for assessing risk of bias guided by the
Cochrane Handbook for Systematic Reviews of Interven-
tions (version 5.1.0) [32]. Six domains were evaluated: se-
quence generation, allocation sequence concealment,
blinding, incomplete outcome data, selective outcome
reporting, and other sources of bias. The overall risk of
bias in each study was assessed using the following judg-
ments: low, moderate, or high, which was specified in the
study by Ata-Ali [33].
The methodological quality of each nonrandomized
observational study was evaluated by the Newcastle-
Ottawa scale, which consists of three domains: patient
selection (0–4 points), comparability of the study groups
(0–2 points), and assessment of outcome (0–3 points)
[34]. A quality score of 0–9 points was allocated to each
nonrandomized study. RCTs with low risk of bias and
nonrandomized studies achieving ≥ 7 points were con-
sidered to be of high quality.
Statistical analysis
All of the available data were binary outcomes; therefore,
they were combined as pooled odds ratio (OR) with
95 % confidence intervals (CIs). Heterogeneity of out-
comes was diagnosed by Q statistics (with a significance
level set at P = 0.10) and I2 statistics (>75 % indicating
high heterogeneity) [35, 36]. The random-effects model
was used in all analyses to produced more conservative
and cautious estimates [9].
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Subgroup analyses were conducted for the outcomes
of TIVAD-related infections, catheter-related thrombotic
complications, and total major mechanical complica-
tions. Data stratified according to patient’ age, whether
antibiotic prophylaxis was used, whether ultrasound
guidance was used, were analyzed to investigate clinical
factors affecting our outcomes. Sensitivity analyses were
conducted to examine the robustness of the effect by
alternatively using a fixed-effects model. We also did
sensitivity analyses according to two different study de-
signs (RCT and non-randomized cohort study). Only
outcomes with more than one studies were included in
the sensitivity analyses. Publication bias was assessed
using Egger regression asymmetry test [37]. A two-
tailed P value < 0.05 was considered statistically signifi-
cant, except otherwise specified. Statistical analysis was
performed using R software (https://www.r-project.org;
last access 29 March 2016) and Stata software version
12 (StataCorp LP, College Station, USA).
Results
A total of 2106 potentially eligible studies were initially
identified, and 2078 were excluded after screening the ti-
tles and abstracts. The remaining 28 articles were fully
reviewed. Of these, 14 were excluded because the data
were not extractable, two studies were duplicate reports
with different outcomes, and one was a RCT with only
30 days follow-up which did not fulfill the criteria of
minimum follow-up of 180 days in this meta-analysis. In
addition, one study [23] was identified from the citations
of the study by Araujo [15].
Therefore, 12 studies [15–18, 21, 23, 31, 38–42] in-
cluding 3905 patients (1824 patients in the IJV group
and 2081 patients in the SCV group) published from
2008 to 2015 were included (Fig. 1). Agreement on study
selection between the two reviewers was high (k = 0.94).
Among the included studies, there were three RCTs [16,
39, 41] and two prospective non-randomized controlled
trials [15, 31]. The remaining seven studies [17, 18, 21,
23, 38, 40, 42] were retrospective. The characteristics of
the included studies are summarized in Table 2.
The risk of bias of the RCTs included in this meta-
analysis is summarized in Table 3. Of the three RCTs,
two [16, 39] were considered to have low risk of bias,
and one [41] had a moderate risk of bias. Among the
nine nonrandomized studies, seven [15, 17, 18, 21, 23,
40, 42] were considered to be of high quality, and two
[31, 38] were regarded as being of low quality (Table 4).
Primary outcomes
The pooled data from 11 studies [15–18, 21, 23, 38–42]
that assessed TIVAD-related infections (Fig. 2a) in 3767
patients showed no significant differences between the
IJV and SCV groups (2.53 % and 3.77 %; OR 0.71, 95 %
CI 0.48–1.04; P = 0.081) with no significant between-
study heterogeneity (I2 = 0.0 %; P = 0.963). Catheter-
related thrombotic complications were reported in 11
studies [15–18, 23, 31, 38–42] that investigated 3802 pa-
tients (Fig. 2b). There were no significant differences be-
tween the IJV and SCV groups (2.05 % and 2.05 %; OR
0.76, 95 % CI 0.38–1.51; P = 0.433), with no significant
between-study heterogeneity (I2 = 30.2 %; P = 0.159).
Secondary outcomes
Data on major mechanical complications were available
in 11 studies, [15, 17, 18, 21, 23, 31, 38–42] which evalu-
ated 3665 patients (Fig. 3a). The rate of total major
mechanical complications was significantly higher in the
SCV group than in the IJV group (3.75 % in the IJV
group and 9.70 % in the SCV group; OR 0.38, 95 % CI
0.24–0.61; P < 0.001), with low between-study heterogen-
eity (I2 = 31.6 %; P = 0.147). Additionally, there were
three major mechanical complications that more than
three studies reported: catheter dislocation, malfunction,
and catheter fracture. In other words, these three com-
plications were common. As a result, the data for the
Fig. 1 Flowchart of the literature search and selection process
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Table 2 Baseline characteristics of studies included in the meta-analysis











Range TIVAD IJV SCV
Araujoc [15], 2008 Portugal PC 55.5 (median) 15–83 Mini-sitimplant 512 551 Y N N 1,2,3,4,5 244/363d (median)
Biffi [16], 2009 Italy RCT 51.9 (mean) 18–75 Bard Port 117 123 Y NR Only for SCV 1,2,4,6,7,8 384/360d (median)
Plumhans [31], 2011 Germany PC 56 (mean) 18–85 Bard Port 44 94 Y NR Only for IJV 7,8 6 mo (mean)
Aribaş [38], 2012 Turkey RC 53.8 (mean) 16–84 Polysite 248 99 Y NR Y 1,2,4,7,8 219.5d (mean)
Ribeiro [39], 2012 Brazil RCT < 18 yr NR NR 34 43 Y Y N 1,2,4,6,7,8 14.8/12.6 mo (mean)
Vetter [21], 2013 Germany RC 53 (mean) 2–84 INTRAPORT 71 32 Y Y N 1,2 451d (mean)
Liud [40], 2014 China RC 45.4 (mean) 8–86 Bardport 222 398 Y NR N 1,2,3,4 1079.3/995.2d (mean)
Miao [41], 2014 China RCT 58.1 (mean) 25–81 NR 107 107 Y Y Only for IJV 1,2,3,4,8 215/209d (mean)
Nagasawae [17], 2014 Japan RC 64 (median) 25–85 BARD X-port isp 136 97 NR NR Only for IJV 3 566/402d (mean)
Ozbudak [42], 2014 Turkey RC 56.38 (mean) 14–83 FB Medical/Districlass
medical SA
178 224 Y N Y for some patients 3,8 507d (median)
Wu [18], 2014 Taiwan RC 57.7 (mean) 0.5–94 Arrow/Bard/ Tyco 63 234 Y NR N NA 4.5 yr (mean)
Jung [23], 2015 Korea RC 59 (median) 1–82 Bard Port 92 79 NR NR N 1,2,4,7 278d (median)
Abbreviations: d days, mo months, N No, NR data not reported, PC prospective cohort study, RC retrospective cohort study, US ultrasound guidance, Y Yes, yr years
afor matching criteria: 1 = age; 2 = gender; 3 = completion of the TIVAD insertion; 4 = site of primary malignancy; 5 = time of surgery; 6 = side; 7 = TIVAD outer diameter; 8 = coagulation parameters; 9 = body mass index
bMean or median dwell time
cOnly 512 and 551 patients were included in the analysis for group IJV and SCV respectively
dOne catheter fracture due to iatrogenic injury was not included in the analysis












three major mechanical complications were pooled for
meta-analysis.
Seven studies [15, 17, 18, 23, 31, 38, 41] that reported
on catheter dislocation in 2463 patients showed a sig-
nificant difference favoring the IJV group (1.08 % in the
IJV group and 2.54 % in the SCV group; OR 0.43, 95 %
CI 0.22–0.84; P = 0.013) (Fig. 3b). Nine studies [15, 18,
21, 23, 31, 39–42] that assessed 3085 patients reported
on malfunction, and the difference was statistically sig-
nificant in favor of the IJV (2.80 % in the IJV group and
5.56 % in the SCV group; OR 0.42, 95 % CI 0.28–0.62;
P < 0.001) (Fig. 3c). Pooling the data of seven studies
[15, 17, 18, 21, 39, 40, 42] including 2795 patients that
reported on catheter fracture showed no significant dif-
ference between the two groups (0.82 % in the IJV
group and 2.91 % in the SCV group; OR 0.47, 95 % CI
0.21–1.05; P = 0.065) (Fig. 3d). All of the three major
mechanical complications showed no significant het-
erogeneity (Fig. 3b, c, and d).
Subgroup analyses
Subgroup analyses showed that use of antibiotic
prophylaxis did not influence the incidence of TIVAD-
related infections (Table 5). In the subgroup analyses of
ultrasound guidance, only one study [38] used
ultrasound to guide the TIVAD insertion for all pa-
tients, and six studies [15, 18, 21, 23, 39, 40] used ana-
tomical landmark technique for all patients (Table 1).
The results showed that the use of ultrasound guidance
did not affect the risks of TIVAD-related infections and
catheter-related thrombotic complications; however, it
moderated the effect size of total major mechanical
complications (Table 5). In addition, subgroup analyses
stratified by the patients’ age showed no change in our
conclusions for the outcomes of TIVAD-related infec-
tions and catheter-related thrombotic complications;
however, in the subgroup of adults, the risk of total
major mechanical complications was not significantly
different between the two groups with higher hetero-
geneity (I2 = 56.5 %; P = 0.100) (Table 5), indicating that
heterogeneity in the total major mechanical complica-
tions was due to other factors, rather than patients’ age.
Sensitivity analyses
Sensitivity analysis by alternatively using a fixed-effects
model did not show any relevant influence on all of the
outcomes except catheter fracture, which showed a re-
duced risk in the IJV group (OR 0.38, 95 % CI 0.18–0.78;
P =0.008) with low heterogeneity (I2 = 0.0 %; P = 0.436)
(Table 6). In the sensitivity analyses, RCTs and non-
Table 4 Newcastle-Ottawa Scale for nonrandomized cohort studies






























Araujo, 2008 1 1 1 1 1 1 1 0 7
Plumhans,
2011
1 1 1 1 1 1 0 0 6
Aribaş, 2012 1 1 1 1 1 1 0 0 6
Vetter, 2013 1 1 1 1 1 1 1 1 8
Liu, 2014 1 1 1 1 0 1 1 1 7
Nagasawa,
2014
1 1 1 1 0 1 1 1 7
Ozbudak, 2014 1 1 1 1 1 1 1 1 8
Wu, 2014 1 1 1 1 1 1 1 1 8
Jung, 2015 1 1 1 1 2 1 1 1 9
Table 3 Cochrane summary assessment of risk of bias for included RCTs







Biffi, 2009 yes yes yes yes yes no low
Ribeiro, 2012 yes uncertain yes yes yes yes low
Miao, 2014 uncertain uncertain yes yes yes no moderate
aFive or six domains with “yes” represents low risk of bias; three or four domains with “yes” represents moderate risk of bias; two or fewer domains with “yes”
represents high risk of bias
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randomized studies showed the same results for the
overall OR estimates for TIVAD-related infections,
catheter-related thrombotic complications, total major
mechanical complications, and malfunction (Table 6).
Publication bias
Publication bias was assessed by Egger regression asym-
metry test, which did not suggest any significant publica-
tion bias for TIVAD-related infections (P = 0.343),
catheter-related thrombotic complications (P = 0.147),
total major mechanical complications (P = 0.502), cath-
eter dislocation (P = 0.959), malfunction (P = 0.265), and
catheter fracture (P = 0.730) among the included studies.
Egger funnel plots for TIVAD-related infections,
catheter-related thrombotic complications, and total
major mechanical complications were shown in Fig. 4.
Discussion
This meta-analysis of three RCTs and nine non-
randomized cohort studies, all of which included a total
of 3905 patients, compared the efficacy of the IJV and
the SCV as the percutaneous access site for a TIVAD.
The results suggested that compared with the SCV, the
IJV seems to be a safer venous access site with signifi-
cantly reduced major mechanical complications. To be
more specific, the IJV is associated with a lower risk of
catheter dislocation and malfunction. We found no sig-
nificant differences in TIVAD-related infections and
thrombotic complications. On subgroup analyses, the
use of antibiotic prophylaxis did not influence the inci-
dence of infectious complications; the use of ultrasound
guidance did not affect the risks of TIVAD-related infec-
tions and catheter-related thrombotic complications, but
Study
Random effects model
Heterogeneity: I-squared=0%, tau-squared=0, p=0.963






































































































b. Catheter-related thrombotic complications
Random effects model
Heterogeneity: I-squared=30.2%, tau-squared=0.3664, p=0.159
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Favors IJV                     Favors SCV
Fig. 2 Forest plot and meta-analysis of TIVAD-related infections (a) and catheter-related thrombotic complications (b)
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Fig. 3 Forest plot and meta-analysis of major mechanical complications, including total major mechanical complications (a), catheter dislocation
(b), malfunction (c), and catheter fracture (d)
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it moderated the effect size of total major mechanical
complications. On sensitivity analyses, the overall esti-
mates of all endpoints except catheter fracture remain
robust by alternatively using a fixed-effects model; both
RCTs and non-randomized cohort studies showed the
same results for TIVAD-related infections, catheter-
related thrombotic complications, and total major mech-
anical complications.
Easy and reliable vascular access is particularly import-
ant in cancer patients. The introduction of TIVADs has
made the treatment of oncology patients more comfort-
able and convenient, because dressing is not required
and daily activities of the arms need not be restricted
once the port is implanted [43]. Compared with external
indwelling catheters, advantages of the TIVAD include
reduced risk of infection, greater patient acceptance and
requiring less maintenance [3, 44]. However, like other
short-term central venous catheters, TIVAD also pre-
sents risks itself after long-term indwelling.
The rate of TIVAD-related infections in our study was
2.53 % in the IJV group and 3.77 % in the SCV group,
which was consistent with the reported results (3–10 %)
of a recent review [3]. Subgroup analysis showed that
the use of antibiotic prophylaxis did not influence the
overall estimates for infections. We did not find a signifi-
cant difference between the two groups in terms of
TIVAD-related infections. Because patients with cancer
are susceptible to infections due to immune depression
and neutropenia [3, 13], we also suggest that measures
should be taken to reduce the risk of infections, includ-
ing sterile precautions during TIVAD insertion, and op-
timal aseptic catheter maintenance [12, 45, 46].
The incidences of catheter-related thrombosis in this
meta-analysis were both 2.05 % in the IJV and in the
SCV group, which were consistent with the results (0.3–
28.3 %) of a review by Verso [47]. Thrombosis repre-
sents a major problem in oncology practice [48]. Cancer
patients are usually at increased risk of venous throm-
bosis [49]. Although anticoagulant prophylaxis is contro-
versial, routine heparin flushing of the port seems to be
sufficient to prevent thrombosis formation [12]. In this
meta-analysis, the majority of included studies reported
on use of heparinized saline flushing regularly for pri-
mary prevention of catheter-associated thrombosis, and
Table 5 Subgroup analyses comparing IJV versus SCVa
Group TIVAD-related infections Catheter-related thrombotic complications Total major mechanical complications
N OR (95 % CI) I2(%) Pheterogeneity N OR (95 % CI) I
2(%) Pheterogeneity N OR (95 % CI) I
2(%) Pheterogeneity
Overall 11 0.71 (0.48–1.04) 0.0 0.963 11 0.76 (0.38–1.51) 30.2 0.159 11 0.38 (0.24–0.61) 31.6 0.147
Use of antibiotic prophylaxis
Yes 3 0.69 (0.27–1.76) 0.0 0.611 NA NA NA NA NA NA NA NA
No 2 0.69 (0.39–1.24) 0.0 0.618 NA NA NA NA NA NA NA NA
Use of ultrasound guidance
Yes 1 0.40 (0.02–6.41) NA NA 1 1.00 (0.19–5.23) NA NA 1 0.39 (0.08–1.98) NA NA
No 6 0.76 (0.47–1.24) 0.0 0.798 5 0.44 (0.18–1.05) 0.0 0.860 6 0.38 (0.18–0.79) 46.3 0.098
Age Group
< 18 yr 1 0.50 (0.14–1.80) NA NA 1 0.41 (0.02–10.40) NA NA 1 0.27 (0.10–0.76) NA NA
≥ 18 yr 3 0.44 (0.16–1.22) 0.0 0.972 4 1.13 (0.28–4.61) 56.8 0.073 3 0.61 (0.15–2.56) 56.5 0.100
Abbreviations: N Number of studies, NA not applicable, yr years old
aAll these analyses were performed with random-effects model
Table 6 Sensitivity analyses comparing IJV versus SCV
Outcomes OR (95 % CI)
Base casea Using fixed-effects model RCTs includeda Non-randomized cohort
studies includeda
TIVAD-related infections 0.71 (0.48–1.04) 0.70 (0.47–1.03) 0.47 (0.17–1.28) 0.76 (0.50–1.16)
Catheter-related thrombotic complications 0.76 (0.38–1.51) 0.91 (0.57–1.43) 0.90 (0.17–4.68) 0.56 (0.27–1.16)
Total major mechanical complications 0.38 (0.24–0.61) 0.36 (0.26–0.49) 0.30 (0.17–0.53) 0.44 (0.22–0.88)
Catheter dislocation 0.43 (0.22–0.84) 0.43 (0.23–0.83) NAb 0.40 (0.15–1.07)
Malfunction 0.42 (0.28–0.62) 0.42 (0.28–0.62) 0.28 (0.12–0.64) 0.47 (0.30–0.74)
Catheter fracture 0.47 (0.21–1.05) 0.38 (0.18–0.78) NAb 0.50 (0.15–1.61)
Abbreviation: NA not applicable
aRandom-effects model was used in these analyses
bSensitivity analysis was not conducted because only one study was included
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only two studies [17, 23] did not mention the use of
heparin for routine maintenance of the TIVAD, which,
however, did not mean heparin was not used. Actually,
prophylactic heparin flushing has become the routine of
clinical practice [50]. Consequently, subgroup analysis
stratified by whether heparin was used was not con-
ducted. Furthermore, placement of the catheter tip low
in the SVC or at the atriocaval junction resulted in a
lower risk of thrombosis than placement higher in the
SVC [51, 52]. As a result, the use of fluoroscopy after
implantation was recommended to identify tip position
and ensure adequate catheter length (catheter tip below
the T3 level) [52]. When thrombosus occurs, we may re-
sort to medical treatment (anticoagulant agents or
thrombolytic drugs) or even remove the TIVAD [48].
Catheter dislocation (also defined as a secondary mal-
position) can occur months after implantation of the
TIVAD if the catheter tip is dislocated from its original
position [2, 13]. Radiological control of the catheter tip
using chest fluoroscopy after implantation is mandatory
[12, 53]. In fact, all the included studies in this meta-
analysis used fluoroscopy to confirm the catheter tip in
the right place. The reason why catheter dislocation is
more common in SCV group is still unclear. However,
according to a retrospective study by Paleczny [14],
spontaneous dislocation of the vascular port and cath-
eter tip associated with changes in body position was
found by chest radiograph in two patients with the cath-
eters placed only in the SCV rather than in the IJV
group. This phenomenon indicates that TIVAD insertion
via the SCV route may be more subject to spontaneous
dislocation when changing body position in daily life.
The pinch-off syndrome is specifically associated with
the SCV approach [54]. Due to the compression of an
implantable port between the clavicle and the first rib,
the pinch-off syndrome can result in mechanical com-
pression and shearing forces on the catheter lines [55],
which may lead to malfunction, damage, and even frac-
ture of the catheter after material fatigue [56], with
embolization in the lung vascular bed. Pinch-off
syndrome serves as a warning prior to catheter fracture,
a rare but serious complication [57]. We confirmed that
compared with IJV, SCV was associated with more inci-
dences of major mechanical complications and many
(malfunction, damage and catheter fracture) may be due
to pinch-off syndrome.
Our meta-analysis is unique and presents important
implications for clinicians in that, to our knowledge, it is
the first study to systematically summarize the associ-
ation of venous access sites for percutaneous implant-
ation of a TIVAD and long-term morbidity. We used a
comprehensive search strategy and systematic review
method, following the MOOSE guidelines and the
PRISMA statement. We limited heterogeneity by includ-
ing only studies with more than 180 days follow-up. Fur-
thermore, we redefined the outcome of malfunction to
cover all aspects of catheter malfunctioning, namely
infusion and aspiration malfunction as well as a combin-
ation of both [29], thereby avoiding potential heterogen-
eity in the endpoint of malfunction. Moreover,
heterogeneity was low to moderate in the analyses of all
outcomes, suggesting that variations in findings are
compatible with chance alone and not likely to be
caused by genuine differences between studies [58].
Our study has the following limitations. First, the ma-
jority of included studies were not RCTs and often pre-
sented a small sample size. They were carried out in
hospitals with different protocols and likely different
levels of physician expertise. Second, the definitions of
endpoints such as TIVAD-related infections, catheter-
related thrombotic complications, were not clearly de-
scribed in some studies; however, studies were pooled
irrespective of their definitions of these endpoints. The
heterogeneity in endpoint reporting of the primary
studies should be considered as a limitation. Third, in
the subgroup analysis, ultrasound guidance diminished
the advantage of IJV for the outcome of total major
mechanical complications. However, this result should
be interpreted with caution, because only one study
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Fourth, the implantation of a TIVAD can be performed
by surgical venous cut-down technique and percutan-
eous approaches [43], and the results of our meta-
analysis only apply to percutaneous approaches. Fifth,
some definitions of mechanical complications (port ro-
tation, port extrusion, hemorrhage, and extravasation)
were not sufficiently described; these outcomes were
included in the outcome of total major mechanical
complications and were not individually pooled for
meta-analysis. Sixth, because the raw data of the in-
cluded studies were not available and both arms were
comparable in terms of the follow-up period in each
study, the results of the analysis did not take into ac-
count of the number of catheter days. However, as the
cumulative risk of infectious, thrombotic, and mechan-
ical complications increased with increasing catheter
exposure, the complications might have been underesti-
mated due to the relatively short follow-up period in
some studies [31, 41].
Conclusions
In conclusion, in the present meta-analysis comparing
the IJV and the SCV as a venous access site for percu-
taneous insertion of a TIVAD, we identified a better
choice of the IJV in terms of the incidence of major
mechanical complications (catheter dislocation and mal-
function), but we did not find any statistically significant
differences in TIVAD-related infections and thrombotic
complications. Given the inherent limitations of the in-
cluded studies, the findings from our study must be con-
firmed and updated in a large-scale and well-designed
RCT with long-term follow-up.
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